Journal
JOURNAL OF CONTROLLED RELEASE
Volume 271, Issue -, Pages 98-106Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jconrel.2017.12.022
Keywords
Liposomes; siRNA; Protamine; Aptamers; Cancer stem cell; CD44
Funding
- AL HIKMA pharmaceutical company
- The French Embassy in Amman
Ask authors/readers for more resources
In this study, we describe a liposome-based siRNA delivery system with a core composed of siRNA: protamine complex and a shell designed for the active targeting of CD44-expressing cells using for the first time the anti-CD44 aptamer (named Apt1) as targeting ligand. Among all functions, CD44 is the most common cancer stem cell surface biomarker and is found overexpressed in many tumors making this an attractive receptor for therapeutic targeting. This unique non-cationic system was evaluated for the silencing of the reporter gene of luciferase (luc2) in a triple-negative breast cancer model in vitro and in vivo. We show the possibility of conjugating an aptamer to siRNA-containing liposomes for an efficient gene silencing in CD44-expressing tumor cells in vivo, in the perspective of silencing disease-related genes in tumors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available